A phase I clinical trial was conducted targeting glioblastoma patients with a drug (NCT03374943) that regulates the protein level of EPHA3, which we identified as the final player in the epigenetic regulome associated with the aggressiveness of HCC. This evidence concerns the gene EPHA3 and hepatocellular carcinoma.